-
at 0.2 μM for PV patient progenitor cells.
-
estimated at 0.2 μM for PV patient progenitor cells.
-
osteogenesis-inducing activity in multipotent mesenchymal progenitor cells. Similar studies have reported purmorphamine to enhance
-
It is also used as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT
-
to induce mouse C2C12 myoblast cells to become multipotent mesenchymal progenitor cells in the concentration range
-
of the pluripotency genes Oct4. It is reported that BIX-01294 enhances reprogramming efficiency of neural progenitor
-
of its progenitor, Cisplatin (sc-200896), the first of this class of antineoplastic agents. The action of this group
-
chemokine 24, Small-inducible cytokine A24, Myeloid progenitor inhibitory factor 2, CK-beta-6, Eosinophil chemotactic
-
chemokine 24, Small-inducible cytokine A24, Myeloid progenitor inhibitory factor 2, CK-beta-6, Eosinophil chemotactic
-
of its progenitor, Cisplatin , the first of this class of anti-neoplastic agents. Oxaliplatin displays higher